‘Rope Not Dope’ Still Convince Congress On Hemp?
Failing to maintain key non-intoxicating distinction for hemp could cost US market its future. FDA appointment of senior policy advisor for cannabis could change things.
You may also be interested in...
Calling Congress’s failure to include cosmetic and dietary supplement riders in recent FDA user-fee reauthorization “a profound missed opportunity,” former FDA commissioners push for movement in the lame duck Congress in December.
Hemp industry and private attorneys glad Birenbaum, who was the chief cannabis policy advisor to governors of New York and Rhode Island, given prominent role at FDA that could spur regulatory action.
While not asking Science Board for recommendations on allowing lawful use of hemp in non-drug products, agency officials gave clear indication of current position on the question.